ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

1,4-Diazabicyclo(2.2.2)octane--trimethylalumane (1/2) → 2-N-Methyl-2-N-phenyl-6-{5-[(4-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}piperidin-1-yl)carbonyl]-1,2,4-oxadiazol-3-yl}-1,3,5-triazine-2,4-diamine

HRID 341449
印刷

反応式

HRID 341449 の反応式
C[Al](C)C.C[Al](C)C.C1N2CCN(CC2)C1.Cl.[F:18][C:19]([F:30])([F:29])[CH2:20][S:21][CH2:22][CH:23]1[CH2:28][CH2:27][NH:26][CH2:25][CH2:24]1.[NH2:31][C:32]1[N:37]=[C:36]([N:38]([CH3:45])[C:39]2[CH:44]=[CH:43][CH:42]=[CH:41][CH:40]=2)[N:35]=[C:34]([C:46]2[N:50]=[C:49]([C:51](OCC)=[O:52])[O:48][N:47]=2)[N:33]=1>C1COCC1>[CH3:45][N:38]([C:39]1[CH:44]=[CH:43][CH:42]=[CH:41][CH:40]=1)[C:36]1[N:37]=[C:32]([NH2:31])[N:33]=[C:34]([C:46]2[N:50]=[C:49]([C:51]([N:26]3[CH2:27][CH2:28][CH:23]([CH2:22][S:21][CH2:20][C:19]([F:29])([F:18])[F:30])[CH2:24][CH2:25]3)=[O:52])[O:48][N:47]=2)[N:35]=1
参加物実験手順後処理出典と根拠反応ノート

参加物

5

反応物 3

HCID 166883661,4-Diazabicyclo(2.2.2)octane--trimethylalumane (1/2)HCID 668028784-{[(2,2,2-Trifluoroethyl)sulfanyl]methyl}piperidine hydrochloride2 回HCID 66803067Ethyl 3-{4-amino-6-[methyl(phenyl)amino]-1,3,5-triazin-2-yl}-1,2,4-oxadiazole-5-carboxylate

生成物 1

HCID 668031492-N-Methyl-2-N-phenyl-6-{5-[(4-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}piperidin-1-yl)carbonyl]-1,2,4-oxadiazol-3-yl}-1,3,5-triazine-2,4-diamine
収率 11%

試薬・触媒・溶媒 1

HCID 8028Tetrahydrofuran溶媒

実験手順

Bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane adduct (225 mg, 0.88 mmol) was added to 4-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}piperidine hydrochloride (Intermediate 267, 219 mg, 0.88 mmol) in dry THF (6 mL) in a sealed tube at room temperature. The reaction mixture was stirred at 40 C for 2 h. Ethyl 3-{4-amino-6-[methyl(phenyl)amino]-1,3,5-triazin-2-yl}-1,2,4-oxadiazole-5-carboxylate (prepared in an analogous manner to Example 73, 200 mg, 0.58 mmol) was added at 40 C. The reaction was heated at 80 C for 2 h before being concentrated under vacuum. The residue was taken up in DMSO (6 mL) and the inorganic residue was filtered off. The filtrate was purified by preparative HPLC, Method C, to provide two batches of the title compound (batch 1: 33 mg, 11%). Some impure product was recovered from the preparative HPLC purification, this material was concentrated, diluted with water (50 mL), acidified with a 1N aq. solution of HCl (to pH 4) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (50 mL) and dried over magnesium sulfate. This crude material was then purified by preparative HPLC, Method C, to provide the title compound (Batch 2: 83 mg, 28%).

後処理

  1. additionwas added at 40 C
  2. temperatureThe reaction was heated at 80 C for 2 h
  3. concentrationbefore being concentrated under vacuum
  4. filtrationthe inorganic residue was filtered off
  5. customThe filtrate was purified by preparative HPLC, Method C

出典と根拠

ORDレコード
ord-74ecfa6718914b858144cdf6b5febd1c
出典データセット
uspto-grants-2014_11
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08895733B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート